Literature DB >> 26361237

Serum Shiga toxin 2 values in patients during acute phase of diarrhoea-associated haemolytic uraemic syndrome.

Xiaohua He1, Beatriz Quiñones2, Maroeska Te Loo3, Sebastian Loos4, Gaia Scavia5, Maurizio Brigotti6, Elena Levtchenko7, Leo Monnens8.   

Abstract

AIM: Shiga toxins are delivered via systemic circulation and are considered to be the cause of diarrhoea-associated haemolytic uraemic syndrome (HUS), as they injure endothelial cells, particularly in the glomeruli. This study measured Shiga toxin 2 (Stx2) in the serum of children affected in by HUS due to Stx2 producing Escherichia coli.
METHODS: The concentration of free Stx2 was measured in the serum of 16 children, collected immediately after admission to the clinic in the acute phase of HUS, using a sandwich enzyme-linked immunosorbent assay. The family members of two children were also investigated, with the relative toxicity of Stx2 assessed by a Vero cell-based fluorescent assay.
RESULTS: Stx2 was found in the serum of eight of the 16 children who were investigated. It was also detected in four of the six family members not showing symptomatic HUS, with an extremely high level in two.
CONCLUSION: An absent or rather low concentration of Stx2 was found in the serum of children admitted to the clinic with diarrhoea-associated HUS. The high concentration of Stx2 in family members without HUS, but mostly with watery diarrhoea and raised functional activity, was in line with the concept of early injury by Stx2. ©2015 Foundation Acta Paediatrica. Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  Foodborne pathogen; Functional assay of Stx-2; Haemolytic uraemic syndrome; Shiga toxin

Mesh:

Substances:

Year:  2015        PMID: 26361237     DOI: 10.1111/apa.13211

Source DB:  PubMed          Journal:  Acta Paediatr        ISSN: 0803-5253            Impact factor:   2.299


  7 in total

1.  C3 levels and acute outcomes in Shiga toxin-related hemolytic uremic syndrome.

Authors:  Alejandro Balestracci; Luciana Meni Bataglia; Ismael Toledo; Laura Beaudoin; Caupolican Alvarado
Journal:  Pediatr Nephrol       Date:  2019-09-02       Impact factor: 3.714

2.  LPS-primed CD11b+ leukocytes serve as an effective carrier of Shiga toxin 2 to cause hemolytic uremic syndrome in mice.

Authors:  Shuo Niu; John Paluszynski; Zhen Bian; Lei Shi; Koby Kidder; Yuan Liu
Journal:  Sci Rep       Date:  2018-03-05       Impact factor: 4.379

3.  The structure of the Shiga toxin 2a A-subunit dictates the interactions of the toxin with blood components.

Authors:  Maurizio Brigotti; Dorothea Orth-Höller; Domenica Carnicelli; Elisa Porcellini; Elisabetta Galassi; Pier Luigi Tazzari; Francesca Ricci; Francesco Manoli; Ilse Manet; Heribert Talasz; Herbert H Lindner; Cornelia Speth; Thomas Erbeznik; Stefan Fuchs; Wilfried Posch; Sneha Chatterjee; Reinhard Würzner
Journal:  Cell Microbiol       Date:  2019-01-18       Impact factor: 3.715

Review 4.  Verotoxin Receptor-Based Pathology and Therapies.

Authors:  Clifford Lingwood
Journal:  Front Cell Infect Microbiol       Date:  2020-03-31       Impact factor: 5.293

5.  Shiga Toxin Uptake and Sequestration in Extracellular Vesicles Is Mediated by Its B-Subunit.

Authors:  Annie Willysson; Anne-Lie Ståhl; Daniel Gillet; Julien Barbier; Jean-Christophe Cintrat; Valérie Chambon; Anne Billet; Ludger Johannes; Diana Karpman
Journal:  Toxins (Basel)       Date:  2020-07-10       Impact factor: 4.546

6.  A rapid and sensitive method to measure the functional activity of Shiga toxins in human serum.

Authors:  Valentina Arfilli; Domenica Carnicelli; Gianluigi Ardissino; Erminio Torresani; Gaia Scavia; Maurizio Brigotti
Journal:  Toxins (Basel)       Date:  2015-11-04       Impact factor: 4.546

Review 7.  Microvesicle Involvement in Shiga Toxin-Associated Infection.

Authors:  Annie Villysson; Ashmita Tontanahal; Diana Karpman
Journal:  Toxins (Basel)       Date:  2017-11-19       Impact factor: 4.546

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.